Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 01-Jun-23 4:21 PM View:  | Justice Angela Chief People Officer | Tcr2 Therapeutics Inc. (TCRR) | 01-Jun-23 | Disposition | 48,745 | -- | -- | (100%) 48.74K to 0 | |
| 14-Feb-24 5:25 PM View: | Tang Kevin C 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 01-Jun-23 | Disposition (other) | 4,394,800 | -- | -- | (100%) 4.39M to 0 | |
| 01-Jun-23 4:27 PM View: | Olagunju Peter Chief Operating Officer | Tcr2 Therapeutics Inc. (TCRR) | 01-Jun-23 | Disposition | 24,092 | -- | -- | (100%) 24.09K to 0 | |
| 05-Jun-23 4:36 PM View: | Mpm Bioventures 2014, L.P. 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 01-Jun-23 | Disposition (other) | 4,158,960 | -- | -- | (100%) 4.16M to 0 | |
| 01-Jun-23 4:22 PM View: | Menzel Garry E President and CEO Director | Tcr2 Therapeutics Inc. (TCRR) | 01-Jun-23 | Disposition | 138,871 | -- | -- | (100%) 138.87K to 0 | |
| 05-Jun-23 4:36 PM View: | Mpm Sunstates Fund, L.P. 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 01-Jun-23 | Disposition (other) Duplicate | 4,158,960 | -- | -- | (100%) 4.16M to 0 | |
| 05-Jun-23 4:37 PM View: | Ubs Oncology Impact Fund L.P. 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 01-Jun-23 | Disposition (other) | 3,370,980 | -- | -- | (100%) 3.37M to 0 | |
| 01-Jun-23 4:29 PM View: | Cardama Alfonso Quintas Chief Medical Officer | Tcr2 Therapeutics Inc. (TCRR) | 01-Jun-23 | Disposition | 109,459 | -- | -- | (100%) 109.46K to 0 | |
| 05-Jun-23 4:35 PM View: | Gadicke Ansbert Director 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 01-Jun-23 | Disposition (other) | 7,529,950 | -- | -- | (100%) 7.53M to 0 | |
| 01-Jun-23 4:22 PM View: | Menzel Garry E President and CEO Director | Tcr2 Therapeutics Inc. (TCRR) | 01-Jun-23 | Disposition | 265,459 | -- | -- | (66%) 404.33K to 138.87K | |
| 30-May-23 8:02 PM View: | Tang Kevin C 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 25-May-23 | Private Purchase | 50,000 | $1.72 | $86,000.00 | 1% 4.34M to 4.39M | |
| 24-May-23 4:38 PM View: | Gadicke Ansbert Director 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 22-May-23 | Exercise (in-the money or at-the-money) Duplicate | 178,269 | $0.74 | $131,919.00 | 2% 7.42M to 7.6M | |
| 24-May-23 4:39 PM View: | Mpm Asset Management LLC 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 22-May-23 | Sale | 70,170 | $1.88 | $131,920.00 | (2%) 3.75M to 3.67M | |
| 24-May-23 4:39 PM View: | Mpm Asset Management LLC 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 22-May-23 | Exercise (in-the money or at-the-money) | 178,269 | $0.74 | $131,919.00 | 5% 3.57M to 3.75M | |
| 24-May-23 4:38 PM View: | Gadicke Ansbert Director 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 22-May-23 | Sale Duplicate | 70,170 | $1.88 | $131,920.00 | (< 1%) 7.6M to 7.53M | |
| 15-May-23 5:12 PM View: | Tang Kevin C 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 12-May-23 | Purchase | 6,183 | $1.95 | $12,056.90 | < 1% 4.34M to 4.34M | |
| 15-May-23 5:12 PM View: | Tang Kevin C 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 11-May-23 | Private Purchase | 38,765 | $1.95 | $75,591.80 | < 1% 4.3M to 4.34M | |
| 10-May-23 7:02 PM View: | Tang Kevin C 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 10-May-23 | Purchase | 6,774 | $1.95 | $13,209.30 | < 1% 4.29M to 4.3M | |
| 10-May-23 7:02 PM View: | Tang Kevin C 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 09-May-23 | Purchase | 20,141 | $1.95 | $39,274.90 | < 1% 4.27M to 4.29M | |
| 10-May-23 7:02 PM View: | Tang Kevin C 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 08-May-23 | Private Purchase | 57,073 | $1.95 | $111,292.00 | 1% 4.22M to 4.27M | |
| 05-May-23 6:52 PM View: | Tang Kevin C 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 05-May-23 | Purchase | 166,823 | $1.92 | $319,806.00 | 4% 4.05M to 4.22M | |
| 05-May-23 6:52 PM View: | Tang Kevin C 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 04-May-23 | Purchase | 104,241 | $1.86 | $193,888.00 | 3% 3.94M to 4.05M | |
| 05-May-23 6:52 PM View: | Tang Kevin C 10% Owner | Tcr2 Therapeutics Inc. (TCRR) | 03-May-23 | Private Purchase | 18,513 | $1.85 | $34,249.10 | < 1% 3.93M to 3.94M | |
| 13-Dec-22 8:26 PM View: | Cardama Alfonso Quintas Chief Medical Officer | Tcr2 Therapeutics Inc. (TCRR) | 13-Dec-22 | Sale (Planned) | 4,752 | $1.06 | $5,041.87 | (2%) 237.47K to 232.72K | |
| 13-Dec-22 8:19 PM View: | Menzel Garry E President and CEO Director | Tcr2 Therapeutics Inc. (TCRR) | 13-Dec-22 | Sale (Planned) | 11,000 | $1.06 | $11,682.00 | (2%) 586.14K to 575.14K | |
| 13-Dec-22 8:24 PM View: | Olagunju Peter Chief Technical Officer | Tcr2 Therapeutics Inc. (TCRR) | 13-Dec-22 | Sale (Planned) | 1,659 | $1.07 | $1,766.84 | (3%) 54.67K to 53.01K | |
| 13-Dec-22 8:26 PM View: | Cardama Alfonso Quintas Chief Medical Officer | Tcr2 Therapeutics Inc. (TCRR) | 12-Dec-22 | Sale (Planned) | 4,586 | $1.10 | $5,040.01 | (2%) 242.06K to 237.47K | |
| 13-Dec-22 8:19 PM View: | Menzel Garry E President and CEO Director | Tcr2 Therapeutics Inc. (TCRR) | 12-Dec-22 | Sale (Planned) | 10,613 | $1.10 | $11,674.30 | (2%) 596.75K to 586.14K | |
| 13-Dec-22 8:24 PM View: | Olagunju Peter Chief Technical Officer | Tcr2 Therapeutics Inc. (TCRR) | 12-Dec-22 | Sale (Planned) | 1,610 | $1.10 | $1,766.17 | (3%) 56.28K to 54.67K | |
| 13-Dec-22 8:21 PM View: | Justice Angela Chief People Officer | Tcr2 Therapeutics Inc. (TCRR) | 12-Dec-22 | Sale (Planned) | 5,828 | $1.08 | $6,298.30 | (5%) 111.94K to 106.11K | |
| 13-Dec-22 8:19 PM View: | Menzel Garry E President and CEO Director | Tcr2 Therapeutics Inc. (TCRR) | 09-Dec-22 | Sale (Planned) | 10,325 | $1.13 | $11,677.60 | (2%) 607.08K to 596.75K | |
| 13-Dec-22 8:24 PM View: | Olagunju Peter Chief Technical Officer | Tcr2 Therapeutics Inc. (TCRR) | 09-Dec-22 | Sale (Planned) | 1,561 | $1.13 | $1,765.49 | (3%) 57.84K to 56.28K | |
| 13-Dec-22 8:21 PM View: | Justice Angela Chief People Officer | Tcr2 Therapeutics Inc. (TCRR) | 09-Dec-22 | Sale (Planned) | 2,792 | $1.13 | $3,149.38 | (2%) 114.73K to 111.94K | |
| 13-Dec-22 8:26 PM View: | Cardama Alfonso Quintas Chief Medical Officer | Tcr2 Therapeutics Inc. (TCRR) | 09-Dec-22 | Sale (Planned) | 4,461 | $1.13 | $5,040.93 | (2%) 246.52K to 242.06K | |
| 09-Dec-22 4:43 PM View: | Justice Angela Chief People Officer | Tcr2 Therapeutics Inc. (TCRR) | 08-Dec-22 | Sale (Planned) | 2,511 | $1.25 | $3,151.30 | (2%) 122.21K to 119.7K | |
| 09-Dec-22 4:53 PM View: | Cardama Alfonso Quintas Chief Medical Officer | Tcr2 Therapeutics Inc. (TCRR) | 08-Dec-22 | Sale (Planned) | 4,014 | $1.26 | $5,041.58 | (2%) 258.47K to 254.46K | |
| 09-Dec-22 4:44 PM View: | Menzel Garry E President and CEO Director | Tcr2 Therapeutics Inc. (TCRR) | 08-Dec-22 | Sale (Planned) | 9,314 | $1.25 | $11,679.80 | (1%) 634.82K to 625.5K | |
| 09-Dec-22 4:42 PM View: | Olagunju Peter Chief Technical Officer | Tcr2 Therapeutics Inc. (TCRR) | 08-Dec-22 | Sale (Planned) | 1,410 | $1.25 | $1,766.73 | (2%) 62.04K to 60.63K | |
| 09-Dec-22 4:53 PM View: | Cardama Alfonso Quintas Chief Medical Officer | Tcr2 Therapeutics Inc. (TCRR) | 07-Dec-22 | Sale (Planned) | 3,928 | $1.28 | $5,039.62 | (1%) 262.4K to 258.47K | |
| 09-Dec-22 4:44 PM View: | Menzel Garry E President and CEO Director | Tcr2 Therapeutics Inc. (TCRR) | 07-Dec-22 | Sale (Planned) | 9,111 | $1.28 | $11,680.30 | (1%) 643.93K to 634.82K | |
| 09-Dec-22 4:42 PM View: | Olagunju Peter Chief Technical Officer | Tcr2 Therapeutics Inc. (TCRR) | 07-Dec-22 | Sale (Planned) | 1,378 | $1.28 | $1,766.60 | (2%) 63.42K to 62.04K | |
| 09-Dec-22 4:43 PM View: | Justice Angela Chief People Officer | Tcr2 Therapeutics Inc. (TCRR) | 07-Dec-22 | Sale (Planned) | 2,457 | $1.28 | $3,149.87 | (2%) 124.67K to 122.21K | |
| 07-Dec-22 7:56 PM View: | Menzel Garry E President and CEO Director | Tcr2 Therapeutics Inc. (TCRR) | 06-Dec-22 | Sale (Planned) | 14,886 | $1.35 | $20,081.20 | (2%) 682.23K to 667.34K | |
| 07-Dec-22 7:56 PM View: | Olagunju Peter Chief Technical Officer | Tcr2 Therapeutics Inc. (TCRR) | 06-Dec-22 | Sale (Planned) | 1,327 | $1.33 | $1,764.91 | (2%) 67.36K to 66.04K | |
| 07-Dec-22 7:54 PM View: | Justice Angela Chief People Officer | Tcr2 Therapeutics Inc. (TCRR) | 06-Dec-22 | Sale (Planned) | 2,361 | $1.33 | $3,149.57 | (2%) 131.69K to 129.33K | |
| 07-Dec-22 7:56 PM View: | Cardama Alfonso Quintas Chief Medical Officer | Tcr2 Therapeutics Inc. (TCRR) | 06-Dec-22 | Sale (Planned) | 3,778 | $1.33 | $5,039.85 | (1%) 273.64K to 269.86K | |
| 07-Dec-22 7:54 PM View: | Justice Angela Chief People Officer | Tcr2 Therapeutics Inc. (TCRR) | 05-Dec-22 | Sale (Planned) | 2,302 | $1.37 | $3,160.65 | (2%) 133.99K to 131.69K | |
| 07-Dec-22 7:56 PM View: | Cardama Alfonso Quintas Chief Medical Officer | Tcr2 Therapeutics Inc. (TCRR) | 05-Dec-22 | Sale (Planned) | 3,686 | $1.37 | $5,049.82 | (1%) 277.33K to 273.64K | |
| 07-Dec-22 7:56 PM View: | Menzel Garry E President and CEO Director | Tcr2 Therapeutics Inc. (TCRR) | 05-Dec-22 | Sale (Planned) | 8,530 | $1.37 | $11,703.20 | (1%) 690.76K to 682.23K | |
| 07-Dec-22 7:56 PM View: | Olagunju Peter Chief Technical Officer | Tcr2 Therapeutics Inc. (TCRR) | 05-Dec-22 | Sale (Planned) | 1,291 | $1.37 | $1,766.09 | (2%) 68.66K to 67.36K |
